Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvometinib in Pediatric Langerhans Cell Histiocytosis
NCT07371182Recruiting
- Sponsor
- West China Second University Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of luvometinib in Langerhans cell histiocytosis (LCH), sponsored by West China Second University Hospital. Primary endpoint: Event-Free Survival at 2 years. Started Jun 2026; status: recruiting.
02
Drugs
luvometinib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT07371182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371182.